MSF calls on Japan and South Korea to drop the harmful RCEP measures

Kobe, Japan/New Delhi 22 February 2017 As 16countries negotiating the Regional Comprehensive Economic Partnership (RCEP)agreement meet next week in Kobe, Japan, for the seventeenth round of negotiations, international medical humanitarian organisation Médecins Sans Frontières (MSF) is appealing tothe Japanese and South Korean governmentsto withdraw harmful proposals that will restrict people’s access to affordable generic medicines. While being negotiated behind closed-doors, Japan and South Korea are aggressively pushing for measures in the RCEP agreement that would emphasise stronger pharmaceutical corporation power at the expense of public health, threatening millions of lives globally. Continue reading

Posted in Data Exclusivity, Drug prices, Generics, Patent Term Extension, Regional Comprehensive Economic Partnership, TRIPS, TRIPS plus, Uncategorized | Leave a comment

Compulsory licensing required for essential drugs: Y K Hamied

Pragmatic compulsory licensing policy is needed to enable India to look after health of its people as it cannot afford monopoly in healthcare with the challenges it faces, Cipla’s Y K Hamied said.

Continue reading

Posted in Compulsory Licensing, Uncategorized | Leave a comment

A ‘New’ Recipe for Trade

By Shalini Bhutani, The Economic & Political Weekly (Vol. 52 Issue No. 7)

With other mega regional trade agreements like the Trans–Pacific Partnership in uncertainty, trade treaties like the Regional Comprehensive Economic Partnership will acquire greater significance beyond their original ASEAN-centred grouping. The RCEP needs to be tracked for its implications for both the global trading system and the livelihoods of people.

Continue reading

Posted in IPR policy, Regional Comprehensive Economic Partnership, TPP, Transatlantic Trade and Investment Partnership (TTIP), TRIPS plus, Uncategorized | Leave a comment

Indian pharma at odds with US trade group over USTR Priority Watch List

The tug of war continues. Even as the Indian Pharmaceutical Alliance, the domestic drug industry lobby group, has appealed to the US Trade Representative to remove India from its Priority Watch List – the latter includes countries that are alleged violators of US patent laws – Pharmaceutical Research and Manufacturers of America (PhRMA), in its submission, has requested the USTR to continue to keep India on the Priority Watch List in the 2017 Special 301 Report, reports The Pharma Letter’s India correspondent.

Continue reading

Posted in IP Rights, IPR, IPR policy, Special 301 report, Uncategorized, USTR 301 report | Leave a comment

Healthcare Groups Challenge Patents On Three New Hep-C Drugs In India

Source: Business World

The patent challenges could remove barriers to production and distribution of affordable generic versions of direct-acting antiviral medicines, which are currently sold at very high prices

Patient and healthcare aid groups, including I-MAK and Delhi Network of Positive People (DNP+), supported by Médecins Sans Frontières (MSF) have on Tuesday (Febraury 14) challenged patent rights of three new Hepatitis-C drugs in India. The new drugs, which are currently patent protected in most world markets and are not accessible to poor patients due high costs include sofosbuvir, which is sold under the brand names Sovaldi and soforal etc., by US drug maker and researcher Gilead Sciences, and daclatasvir and velpatasvir, belong to US multinational Bristol Myers Squibb (BMS). Continue reading

Posted in Evergreening, Hepatitis C, Patent Opposition, Sofosbuvir, Uncategorized | Tagged , , | Leave a comment

Healthcare and patient groups oppose patents on crucial hepatitis C drugs

By Rupali Mukherjee, The Times of India 

MUMBAI: Healthcare aid and patient groups have come together in patent courts to fight against “abusive strategies” of Big Pharma, to ensure access to affordable treatment in hepatitis C. The Initiative for Medicines, Access & Knowledge (I-MAK) together with Delhi Network of Positive People and international medical humanitarian organisation, Medecins Sans Frontieres filed three cases on crucial new hepatitis C medicines: two patent challenges on daclatasvir, one on velpatasvir and a further challenge on sofosbuvir. The patent challenges could remove barriers to production and distribution of affordable generic versions of direct-acting antiviral (DAA) medicines, including Gilead’s sofosbuvir and velpatasvir, and Bristol-Myers Squibb’s daclatasvir. Continue reading

Posted in Evergreening, Hepatitis C, Patent Opposition, Sofosbuvir, Uncategorized | Tagged , | Leave a comment

Flawed patents on hepatitis C drugs latest to be challenged in global push for access

Source: MSF Access Campaign

New Delhi/New York, 14 February 2017–Five new challenges against patents on crucial new medicines to treat hepatitis C filed in India and Argentina are the latest in a global push to ensure access to affordable treatment. The patent challenges could remove barriers to production and distribution of affordable generic versions of direct-acting antiviral (DAA) medicines, including sofosbuvir, daclatasvir and velpatasvir.
Posted in Evergreening, Hepatitis C, Patent Opposition, Sofosbuvir, Uncategorized | Tagged , , | Leave a comment